Extending Surgical Resection for Hepatocellular Carcinoma Beyond Barcelona Clinic for Liver Cancer (BCLC) Stage A: A Novel Application of the Modified BCLC Staging System
Ian JY Wee,Fiona NN Moe,Rehena Sultana,Reiko WT Ang,Pearly PS Quek,Brian Kim Poh Goh,Chung Yip Chan,Peng Chung Cheow,Alexander YF Chung,Prema Raj Jeyaraj,Ye Xin Koh,Peter OP Mack,London Lucien PJ Ooi,Ek Khoon Tan,Jin Yao Teo,Juinn Huar Kam,Jacelyn SS Chua,Ashley WY Ng,Jade SQ Goh,Pierce KH Chow
DOI: https://doi.org/10.2147/JHC.S370212
2022-08-18
Journal of Hepatocellular Carcinoma
Abstract:Ian JY Wee, 1 Fiona NN Moe, 1 Rehena Sultana, 2 Reiko WT Ang, 1 Pearly PS Quek, 3 Brian Kim Poh Goh, 1 Chung Yip Chan, 1 Peng Chung Cheow, 1 Alexander YF Chung, 1 Prema Raj Jeyaraj, 1 Ye Xin Koh, 1 Peter OP Mack, 1 London Lucien PJ Ooi, 1 Ek Khoon Tan, 1 Jin Yao Teo, 1 Juinn Huar Kam, 1 Jacelyn SS Chua, 1 Ashley WY Ng, 1 Jade SQ Goh, 1 Pierce KH Chow 1, 4 1 Department of Hepatopancreatobiliary and Transplantation Surgery, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore; 2 Center of Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore; 3 Ministry of Health Holdings, Singapore, Singapore; 4 Surgery Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore Correspondence: Pierce KH Chow, Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, 11 Hospital Drive, Singapore, 169610, Singapore, Tel +65 6576 2151, Email Objective: We aimed to prognosticate survival after surgical resection of HCC stratified by stage with amalgamation of the modified Barcelona Clinic Liver Cancer (BCLC) staging system and location of tumour. Methods: This single-institutional retrospective cohort study included patients with HCC who underwent surgical resection between 1st January 2000 to 30th June 2016. Participants were divided into 6 different subgroups: A-u) Within MC with Unilobar lesions; A-b) Within MC + Bilobar lesions; B1-u) Out of MC + within Up-To-7 + Unilobar lesions; B1-b) Out of MC + within Up-to-7 + Bilobar lesions; B2-u) Out of MC + Out of Up-To-7 + Unilobar lesions; B2-b) Out of MC + Out of Up-To-7 + Bilobar lesions. A separate survival analysis was conducted for solitary HCC lesions according to three subgroups: A-S (Within MC); B1-S (Out of MC + within Up-To-7); B2-S (Out of MC + out of Up-To-7). Results: A total of 794 of 1043 patients with surgical resection for HCC were analysed. Groups A-u (64.6%), A-b (58.4%) and B1-u (56.2%) had 5-year cumulative overall survival (OS) rates above 50% after surgical resection and median OS exceeding 60 months (P = 0.0001). The 5-year cumulative recurrence-free survival rates (RFS) were 40.4% (group A-u), 38.2% (group A-b), 36.3% (group B1-u), 24.6% (group B2-u), and 7.3% (group B2-b)(P=0.0001). For solitary lesions, the 5-year OS for the subgroups were A-S (65.1%), B1-S (56.0%) and B2-S (47.1%) (P = 0.0003). Compared to A-S, there was also a significant trend towards relatively poorer OS as the lesion sizes increased in B1-S (HR 1.46, 95% CI 1.03– 2.08) and B2-S (HR 1.65, 95% CI 1.25– 2.18). Conclusion: We adopted a novel approach combining the modified BCLC B sub-classification and dispersion of tumour to show that surgical resection in intermediate stage HCC can be robustly prognosticated. We found that size prognosticates resection outcomes in solitary tumours. Keywords: hepatocellular carcinoma, surgical resection, Barcelona clinic liver cancer Should indications for surgical resection be extended to intermediate hepatocellular carcinoma? Typically, surgical resection is offered only to patients with hepatocellular carcinomas of an early stage – called Barcelona Liver Cancer Clinic (BCLC) A. Here we adapted the BCLC classification system, showing that if you take the location of the tumour into account as well, you can cure some patients with more advanced BCLC B disease as well. Surgery can cure some patients with BCLC Sub class B1 cancers, if the cancer is confined to one lobe. It should be considered in these patients. Globally, hepatocellular carcinoma (HCC) represents the fourth most common cause of cancer-related mortality. 1 Surgical resection remains the main treatment modality in early HCC provided there is adequate liver function and sufficient future liver remnant. 2 A systematic review of 4209 patients with HCC within the Milan Criteria (MC) demonstrated median 5-year overall survival (OS) of 67% after surgical resection, which crosses 5-year OS of 50% thereby making surgical resection conceptually curative in this group of patients, 3 as first proposed by LLovet and Bruix in 1999 4 and in their subsequent update in 2002. 5 Recent evidence has however suggested that surgical resection may be justifiably offered to select individuals with intermediate- or advanced-stage disease. 6,7 While a number of staging systems have been validated for prognostic evaluation of HCC, there is no universally adopted system. Nevertheless, the Barcelon -Abstract Truncated-
oncology